The problem with most bioplastics is the economics. They promise to degrade in your backyard compost, not the Pacific, but they often cost three or four times more than the petrochemical plastic they’re meant to replace. OliveBio, a Torrance-based biotech, is trying to solve that with a reactor that skips the middleman. Or more precisely, the middle-microbe.
Instead of engineering bacteria to produce polyhydroxyalkanoates (PHAs) inside their cells, OliveBio’s platform uses what it calls an AI-guided cell-free biocatalysis system [OliveBio, retrieved 2024]. The idea is to extract the cellular machinery that makes the polymer and run the reaction in a controlled industrial vat. The goal is a process that is faster, more efficient, and, crucially, cheaper than traditional fermentation. For a material that is fully biodegradable in soil, compost, and marine environments without leaving microplastics, the unit economics are the only thing standing between a niche product and a trillion-dollar market [OliveBio, retrieved 2024].
The bet on a cell-free process
The technical wedge is straightforward. Conventional PHA production relies on feeding sugars to engineered microbes, which then store the polymer as energy reserves inside their cells. You then have to harvest and break open the cells to get the plastic. It’s a biologically elegant but industrially fussy process with multiple steps where yield and cost can leak away. OliveBio’s cell-free approach aims to cut out the living cell’s maintenance costs and complexities, running the polymer-building enzymes directly. The company says its AI component is used to design and optimize these enzymatic pathways for maximum output and minimal waste [Perplexity Sonar Pro Brief, retrieved 2024]. If it works, the result should be a PHA resin that is not just green, but price-competitive with polyethylene or polypropylene.
A team built for the bio-foundry
The founding team leans heavily into deep scientific expertise, a necessity for a bet this technical. CEO Yuliana Mihaylova holds a PhD in Genetics with post-doctoral research from Nottingham and Oxford, and has worked in biotech and pharma management consulting [OliveBio, retrieved 2024]. COO Damian Kao rounds out the operational side. The company describes its team as molecular biologists, geneticists, and bioinformaticians [OliveBio, retrieved 2024]. Their early-stage credibility is underscored by selection into Y Combinator’s Winter 2025 batch and participation in the Stanford LISA - LEAD Incubator & Startup Accelerator. The disclosed pre-seed funding is a relatively modest $500,000, led into by Y Combinator [Tracxn, 2025], which suggests the company is still proving its core technical milestones before a larger industrial raise.
The crowded field of green plastics
OliveBio is not pioneering the PHA category, but trying to reinvent its production. They enter a field with well-funded, established players who have spent years scaling fermentation-based approaches. The competitive set includes companies like Danimer Scientific, which went public via SPAC, and RWDC Industries, which has raised hundreds of millions. The table below outlines the early landscape.
| Company | Primary Approach | Notable Traction |
|---|---|---|
| OliveBio | Cell-free biocatalysis | Y Combinator (2025), Stanford LISA accelerator |
| Danimer Scientific | Microbial fermentation | Publicly traded, supply deals with PepsiCo, Bacardi |
| RWDC Industries | Microbial fermentation | $133M Series B (2020), partnership with Mars |
| Newlight Technologies | Microbial fermentation (using methane) | Commercial product (AirCarbon), partnership with IKEA |
| Full Cycle Bioplastics | Integrated waste-to-PHA process | Focus on organic waste as feedstock |
OliveBio’s membership in the industry association GO!PHA is a small but meaningful signal of intent, placing them within the ecosystem they aim to supply [bioplastics MAGAZINE, March 2025]. The risks here are not subtle.
- The scale-up cliff. Moving from a lab-scale cell-free reaction to thousands of liters at commodity-chemical prices is a notorious valley of death in industrial biotech. The $500,000 pre-seed round is a start, but the capital required to build a pilot plant will be orders of magnitude larger.
- The feedstock question. Even with a more efficient process, the cost of the starting materials (likely plant-based sugars) remains a major input cost. Cheaper processes help, but they don’t eliminate this fundamental tie to agriculture.
- Incumbent momentum. Companies like Danimer have a multi-year headstart, established production capacity, and brand partnerships. OliveBio’ technology must not only work, but work so much better that it justifies customers switching from a proven, if expensive, alternative.
The path to a plastic swap
The next twelve months will be about moving from a promising biological concept to hard, scalable data. The company will need to demonstrate its cost-per-kilogram targets in a relevant pilot environment and likely secure a significantly larger seed round to build that pilot. Success would look like a signed development agreement with a brand or resin converter willing to test their material.
On paper, the math is compelling. Global plastic production is around 400 million metric tons per year. If OliveBio’s process could shave even a few cents per kilogram off the production cost of PHA, it begins to unlock applications in flexible packaging, food service items, and agricultural films,markets currently dominated by conventional plastics. A back-of-the-envelope calculation: replacing just one percent of that global production with PHA would mean a 4-million-ton market. At a conservative price of $3 per kilogram, that’s a $12 billion annual addressable slice. For OliveBio to claim a piece of it, their cell-free reactor must ultimately beat the cost structure of companies like Danimer Scientific, proving that the most elegant biology doesn’t need a cell to be economically viable.
Sources
- [OliveBio, retrieved 2024] OliveBio | Making PHA Bioplastics Scalable and Affordable | https://www.olivebio.com/
- [Perplexity Sonar Pro Brief, retrieved 2024] Web-grounded briefing on OliveBio technology and market positioning
- [Tracxn, 2025] Olive - 2025 Funding Rounds & List of Investors - Tracxn | https://tracxn.com/d/companies/olive/__-f4em4lNE6yI6Lo0IrE15Tsklu43u8PjQvOJjnT2tUA/funding-and-investors
- [bioplastics MAGAZINE, March 2025] Olivebio joins GO!PHA | https://www.bioplasticsmagazine.com/en/news/meldungen/20250307-olivebio.php
- [Power Chronicles, March 2025] Breaking Barriers in Biotech: An Exclusive Interview with Yuliana Mihaylova, CEO of OliveBio | https://powerchronicles.com/breaking-barriers-in-biotech-yuliana-mihaylova-olivebio/
- [RocketReach, retrieved 2026] OliveBio Management Team | Org Chart | https://rocketreach.co/olivebio-management_b6d098dac73e48c2